These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19364691)

  • 1. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
    King AB
    Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
    King AB
    Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.
    Huffman DM; McLean GW; Seagrove MA
    Endocr Pract; 2009; 15(7):689-95. PubMed ID: 19546056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
    Riddle M; Pencek R; Charenkavanich S; Lutz K; Wilhelm K; Porter L
    Diabetes Care; 2009 Sep; 32(9):1577-82. PubMed ID: 19502544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
    Wysham C; Lush C; Zhang B; Maier H; Wilhelm K
    Curr Med Res Opin; 2008 Jan; 24(1):79-85. PubMed ID: 18031595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
    Kovatchev BP; Crean J; McCall A
    Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
    Cohen E; Tsoukas MA; Legault L; Vallis M; Von Oettingen JE; Palisaitis E; Odabassian M; Yale JF; Garfield N; Gouchie-Provencher N; Rutkowski J; Jafar A; Ghanbari M; Haidar A
    Lancet Digit Health; 2024 Jul; 6(7):e489-e499. PubMed ID: 38906614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
    Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
    Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system.
    Jones SM; Quarry JL; Caldwell-McMillan M; Mauger DT; Gabbay RA
    Diabetes Technol Ther; 2005 Apr; 7(2):233-40. PubMed ID: 15857224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
    Sherr JL; Patel NS; Michaud CI; Palau-Collazo MM; Van Name MA; Tamborlane WV; Cengiz E; Carria LR; Tichy EM; Weinzimer SA
    Diabetes Care; 2016 Jul; 39(7):1127-34. PubMed ID: 27208332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
    Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
    Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.
    King AB; Clark D; Wolfe GS
    Endocr Pract; 2012; 18(3):382-6. PubMed ID: 22440988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.